EPS for Q BioMed Inc. (QBIO) Expected At $-0.29

June 14, 2018 - By Kurt Siggers

Q BioMed Inc. (OTCMKTS:QBIO) Logo

Analysts expect Q BioMed Inc. (OTCMKTS:QBIO) to report $-0.29 EPS on July, 18.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.29 EPS. After having $-0.17 EPS previously, Q BioMed Inc.’s analysts see 70.59 % EPS growth. The stock decreased 0.58% or $0.02 during the last trading session, reaching $3.4. About 84,043 shares traded. Q BioMed Inc. (OTCMKTS:QBIO) has 0.00% since June 15, 2017 and is . It has underperformed by 12.57% the S&P500.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company has market cap of $47.51 million. The firm offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer. It currently has negative earnings. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: